RIPK3 and diabetic kidney disease: To further investigate the role of RIPK3 as a molecular target for podocyte injury in DKD treatment, the STZ/HFD/UNI and db/db mice were administered the RIPK3 kinase inhibitor GSK'872 (Figure 7A).